We are very pleased with today's implant result and expect that this will translate into an outstanding clinical success
Madrid, Spain (PRWEB) June 29, 2011
An implantation of a CCM device was performed this Monday in the Leipzig Heart Center in Germany and was broadcast live as part of a special implantable devices session at EUROPACE, Madrid. The Optimizer III device from Impulse Dynamics was implanted in a 57 year old female suffering from chronic heart failure, and presenting with Left Ventricular Ejection Fraction (LVEF) of 30% and paroxysmal atrial fibrillation. The patient had previously received a 1-chamber ICD implantation and recently underwent VT ablation. She is also receiving heart failure medications, but is not adequately responding to treatment.
“Two leads were placed in the right ventricular septum for delivery of CCM signals and a third lead, used for sensing, was placed in the atrium. An impressive acute CCM effect was observed just minutes from initiating CCM signal therapy, with a 19.4% increase in the heart’s contractility (dP/dtmax),” describes Prof. Schmidinger. “In accordance with previous findings, PET-studies performed in our Vienna clinic did not show these effects to be associated with an increase in energy consumption. We are very pleased with the CCM implant result today and expect that this will translate into an outstanding clinical success.”
Cardiac Contractility Modulation (CCM) is a unique and innovative method for treating patients with moderate-to-severe chronic heart failure that are symptomatic despite optimal medical therapy. CCM signals are non-excitatory electric pulses delivered by the Optimizer III implantable device during a specific period of the heart cycle called the absolute refractory period. Research has shown that CCM signals significantly improve the heart’s contractility by normalizing the function and expression of key regulatory proteins in the heart muscle and, through that, the contractility of the heart. Studies in both canine and human subjects have demonstrated that CCM therapy does not result in a detectable increase in myocardial oxygen consumption (MVO2).
“We are happy to report another successful implantation of the Optimizer III device. The Optimizer system is currently the only device-based treatment for the approximately 70 percent of CHF patients with advanced symptoms that have normal QRS duration and, hence, are not suitable for Cardiac Resynchronization Therapy (CRT),” said Dr. Oern Stuge, Impulse Dynamics executive chairman. “The Optimizer III has been implanted in more than 800 patients over the past eight years, and has been shown to significantly improve exercise tolerance and quality of life in implanted patients”.
About Impulse Dynamics
Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure. The Company’s developments are based on its proprietary technology for administrating Cardiac Contractility Modulation (CCM) therapy. The Optimizer III with CCM therapy is CE marked and is available in select excellence centers in Europe and Asia.
For more information please visit http://www.impulse-dynamics.com